Compare · GILD vs PRME
GILD vs PRME
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Prime Medicine Inc. (PRME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and PRME operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.55B, about 301.3x PRME ($532.8M).
- Over the past year, GILD is up 15.0% and PRME is down 26.8% - GILD leads by 41.8 points.
- GILD has been more active in the news (6 items in the past 4 weeks vs 3 for PRME).
- GILD has more recent analyst coverage (25 ratings vs 16 for PRME).
- Company
- Gilead Sciences Inc.
- Prime Medicine Inc.
- Price
- $129.96+0.47%
- $2.98+1.36%
- Market cap
- $160.55B
- $532.8M
- 1M return
- +5.05%
- -5.98%
- 1Y return
- +15.00%
- -26.84%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2022
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 16
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
- Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
- Gilead Sciences downgraded by Leerink Partners with a new price target
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
Latest PRME
- Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
- Prime Medicine Inc. filed SEC Form 8-K: Other Events
- Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
- Prime Medicine upgraded by H.C. Wainwright with a new price target
- Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
- SEC Form 4 filed by Director Schenkein David P
- SEC Form 4 filed by Director Marrazzo Jeffrey D
- SEC Form 4 filed by Director Nelsen Robert
- SEC Form 4 filed by Director Kelly Michael Aaron